Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2 With Hyperglycemia Clinical Trial

Official title:
Comparing the Effects of Hydroxychloroquine (HCQ) to Pioglitazone in Type 2 Diabetic Patients Failing Maximal Doses of Metformin Plus a Sulfonylurea

Status Terminated

Clinical Trial Summary

A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.

Clinical Trial Description

A 4-month, randomized, prospective, open-label comparison trial of 4 months of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea. ;

Study Design

Related Conditions & MeSH terms

Diabetes Mellitus
Diabetes Mellitus Type 2 With Hyperglycemia
Diabetes Mellitus, Type 2
Hyperglycemia

Clinical Trial Details

NCT number	NCT02303405
Study type	Interventional
Source	Charles Drew University of Medicine and Science
Contact
Status	Terminated
Phase	Phase 2
Start date	November 2014
Completion date	November 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03315728` - Pathways for Health Equity Quality Improvement Strategy
Active, not recruiting	`NCT05579561` - Vegetarian Ketogenic Diet VS Omnivore Ketogenic Diet - Protocol of a Keto-vege Diet for Remission of Type 2 Diabetes	N/A
Recruiting	`NCT03269799` - Vitamin C as an Adjunct in Periodontal Treatment in Type 2 Diabetes Mellitus Patients	Phase 2